

Somatostatin Analogs Market Size, Share & Trends Analysis Report By Type (Octreotide, Lanreotide, Pasireotide), By Application (Acromegaly, NET), By End-use (Hospitals, Clinics), By Region, And Segment Forecasts, 2025 - 2030

<https://marketpublishers.com/r/SDB2F6B49E4EEN.html>

Date: May 2025

Pages: 90

Price: US\$ 5,950.00 (Single User License)

ID: SDB2F6B49E4EEN

Abstracts

This report can be delivered to the clients within 3 Business Days

Somatostatin Analogs Market Growth & Trends

The global somatostatin analogs market size is anticipated to reach USD 11.1 billion by 2030 and expand at a CAGR of 13.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing awareness of diseases such as acromegaly and neuroendocrine tumors is expected to be the vital impact rendering driver.

Acromegaly is a chronic endocrine condition caused by excessive growth hormone production, often due to a pituitary adenoma. In 2023, approximately 4,600 people per million globally were affected by acromegaly, with an estimated 116.9 new cases diagnosed annually per million, a number that continues to rise. The disorder is usually diagnosed around age 40 in men and 45 in women, though it often begins in the third decade of life. Hence, the increasing prevalence of acromegaly drives the somatostatin analogs market.

The growing rate of NET diagnoses in countries such as South Korea, Japan, and India and increasing per capita income are significant market drivers. In addition, rising investments from pharmaceutical companies are expected to create lucrative growth opportunities. Existence of different online portals providing related information on various diseases is anticipated to create awareness among the population. For

instance, Neuroendocrine Cancer Awareness Network provides all the information related to their symptoms, available treatment options and disease management.

Somatostatin Analogs Market Highlights

By type, octreotide dominated the somatostatin analogs market, with a revenue share of 36.3% in 2024.

The pasireotide segment is expected to grow at the fastest CAGR over the forecast period.

By application, the NET segment dominated the somatostatin analogs market with the largest revenue share in 2024 and is expected to grow at the fastest CAGR over the forecast period.

Hospitals led the somatostatin analogs market, accounting for the largest revenue share in 2024.

Hospitals dominated the market in 2024, and the clinics segment is expected to grow at the fastest CAGR of 14.4% over the forecast period.

North America dominated the global market owing to the presence of key players in the region.

Companies Mentioned

Novo Nordisk A/S

Pfizer Inc.

Eli Lilly and Company

Medical Device Business Services, Inc.

Johnson & Johnson Services, Inc.

Stryker

Ultragenyx Pharmaceutical Inc.

Alexion Pharmaceuticals, Inc.

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
 - 1.2.1. Type
 - 1.2.2. Application
 - 1.2.3. End Use
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
 - 1.5.1. Purchased Database
 - 1.5.2. GVR's Internal Database
 - 1.5.3. Secondary Sources
 - 1.5.4. Primary Research
- 1.6. Information Analysis
 - 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
 - 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot

CHAPTER 3. SOMATOSTATIN ANALOGS MARKET VARIABLES, TRENDS, & SCOPE

- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
 - 3.2.1. Market Driver Analysis
 - 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
 - 3.3.1. Industry Analysis - Porter's Five Forces Analysis

- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis

CHAPTER 4. SOMATOSTATIN ANALOGS MARKET: TYPE BUSINESS ANALYSIS

- 4.1. Type Market Share, 2024 & 2030
- 4.2. Type Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
- 4.4. Octreotide
 - 4.4.1. Octreotide Market, 2018 - 2030 (USD Million)
- 4.5. Lanreotide
 - 4.5.1. Lanreotide Market, 2018 - 2030 (USD Million)
- 4.6. Pasireotide
 - 4.6.1. Pasireotide Market, 2018 - 2030 (USD Million)
- 4.7. Others
 - 4.7.1. Others Segment Market, 2018 - 2030 (USD Million)

CHAPTER 5. SOMATOSTATIN ANALOGS MARKET: APPLICATION BUSINESS ANALYSIS

- 5.1. Application Market Share, 2024 & 2030
- 5.2. Application Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
- 5.4. Acromegaly
 - 5.4.1. Somatostatin Analogs Market, in Acromegaly, 2018 - 2030 (USD Million)
- 5.5. NET
 - 5.5.1. Somatostatin Analogs Market, in NET, 2018 - 2030 (USD Million)
- 5.6. Others
 - 5.6.1. Somatostatin Analogs Market, in Others, 2018 - 2030 (USD Million)

CHAPTER 6. SOMATOSTATIN ANALOGS MARKET: END USE BUSINESS ANALYSIS

- 6.1. End Use Market Share, 2024 & 2030

6.2. End Use Segment Dashboard

6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)

6.4. Hospitals

6.4.1. Hospitals Segment Market, 2018 - 2030 (USD Million)

6.5. Clinics

6.5.1. Clinics Segment Market, 2018 - 2030 (USD Million)

6.6. Others

6.6.1. Others Segment Market, 2018 - 2030 (USD Million)

CHAPTER 7. SOMATOSTATIN ANALOGS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS

7.1. Regional Market Share Analysis, 2024 & 2030

7.2. Regional Market Dashboard

7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:

7.4. North America

7.4.1. North America Somatostatin Analogs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)

7.4.2. U.S.

7.4.2.1. Key Country Dynamics

7.4.2.2. Regulatory Framework

7.4.2.3. Competitive Insights

7.4.2.4. U.S. Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

7.4.3. Canada

7.4.3.1. Key Country Dynamics

7.4.3.2. Regulatory Framework

7.4.3.3. Competitive Insights

7.4.3.4. Canada Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

7.4.4. Mexico

7.4.4.1. Key Country Dynamics

7.4.4.2. Regulatory Framework

7.4.4.3. Competitive Insights

7.4.4.4. Mexico Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

7.5. Europe

7.5.1. Europe Somatostatin Analogs Market Estimates And Forecasts, By Country,

2018 - 2030 (USD Million)

7.5.2. UK

7.5.2.1. Key Country Dynamics

7.5.2.2. Regulatory Framework

7.5.2.3. Competitive Insights

7.5.2.4. UK Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030

(USD Million)

7.5.3. Germany

7.5.3.1. Key Country Dynamics

7.5.3.2. Regulatory Framework

7.5.3.3. Competitive Insights

7.5.3.4. Germany Somatostatin Analogs Market Estimates And Forecasts, 2018 -

2030 (USD Million)

7.5.4. France

7.5.4.1. Key Country Dynamics

7.5.4.2. Regulatory Framework

7.5.4.3. Competitive Insights

7.5.4.4. France Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030

(USD Million)

7.5.5. Italy

7.5.5.1. Key Country Dynamics

7.5.5.2. Regulatory Framework

7.5.5.3. Competitive Insights

7.5.5.4. Italy Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030

(USD Million)

7.5.6. Spain

7.5.6.1. Key Country Dynamics

7.5.6.2. Regulatory Framework

7.5.6.3. Competitive Insights

7.5.6.4. Spain Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030

(USD Million)

7.5.7. Denmark

7.5.7.1. Key Country Dynamics

7.5.7.2. Regulatory Framework

7.5.7.3. Competitive Insights

7.5.7.4. Denmark Somatostatin Analogs Market Estimates And Forecasts, 2018 -

2030 (USD Million)

7.5.8. Sweden

7.5.8.1. Key Country Dynamics

7.5.8.2. Regulatory Framework

7.5.8.3. Competitive Insights

7.5.8.4. Sweden Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030
(USD Million)

7.5.9. Norway

7.5.9.1. Key Country Dynamics

7.5.9.2. Regulatory Framework

7.5.9.3. Competitive Insights

7.5.9.4. Norway Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030
(USD Million)

7.5.10. Russia

7.5.10.1. Key Country Dynamics

7.5.10.2. Regulatory Framework

7.5.10.3. Competitive Insights

7.5.10.4. Russia Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030
(USD Million)

7.6. Asia Pacific

7.6.1. Asia Pacific Somatostatin Analogs Market Estimates And Forecasts, By
Country, 2018 - 2030 (USD Million)

7.6.2. India

7.6.2.1. Key Country Dynamics

7.6.2.2. Regulatory Framework

7.6.2.3. Competitive Insights

7.6.2.4. India Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030
(USD Million)

7.6.3. China

7.6.3.1. Key Country Dynamics

7.6.3.2. Regulatory Framework

7.6.3.3. Competitive Insights

7.6.3.4. China Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030
(USD Million)

7.6.4. South Korea

7.6.4.1. Key Country Dynamics

7.6.4.2. Regulatory Framework

7.6.4.3. Competitive Insights

7.6.4.4. South Korea Somatostatin Analogs Market Estimates And Forecasts, 2018 -
2030 (USD Million)

7.6.5. Hong Kong

7.6.5.1. Key Country Dynamics

7.6.5.2. Regulatory Framework

7.6.5.3. Competitive Insights

7.6.5.4. Hong Kong Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

7.6.6. Australia

7.6.6.1. Key Country Dynamics

7.6.6.2. Regulatory Framework

7.6.6.3. Competitive Insights

7.6.6.4. Australia Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

7.6.7. Singapore

7.6.7.1. Key Country Dynamics

7.6.7.2. Regulatory Framework

7.6.7.3. Competitive Insights

7.6.7.4. Singapore Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

7.6.8. Japan

7.6.8.1. Key Country Dynamics

7.6.8.2. Regulatory Framework

7.6.8.3. Competitive Insights

7.6.8.4. Japan Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

7.6.9. Thailand

7.6.9.1. Key Country Dynamics

7.6.9.2. Regulatory Framework

7.6.9.3. Competitive Insights

7.6.9.4. Thailand Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

7.7. Latin America

7.7.1. Latin America Somatostatin Analogs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)

7.7.2. Brazil

7.7.2.1. Key Country Dynamics

7.7.2.2. Regulatory Framework

7.7.2.3. Competitive Insights

7.7.2.4. Brazil Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

7.7.3. Argentina

7.7.3.1. Key Country Dynamics

7.7.3.2. Regulatory Framework

7.7.3.3. Competitive Insights

7.7.3.4. Argentina Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

7.8. Middle East & Africa

7.8.1. Middle East & Africa Somatostatin Analogs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)

7.8.2. Kuwait

7.8.2.1. Key Country Dynamics

7.8.2.2. Regulatory Framework

7.8.2.3. Competitive Insights

7.8.2.4. Kuwait Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

7.8.3. Saudi Arabia

7.8.3.1. Key Country Dynamics

7.8.3.2. Regulatory Framework

7.8.3.3. Competitive Insights

7.8.3.4. Saudi Arabia Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

7.8.4. South Africa

7.8.4.1. Key Country Dynamics

7.8.4.2. Regulatory Framework

7.8.4.3. Competitive Insights

7.8.4.4. South Africa Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

7.8.5. UAE

7.8.5.1. Key Country Dynamics

7.8.5.2. Regulatory Framework

7.8.5.3. Competitive Insights

7.8.5.4. UAE Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

CHAPTER 8. COMPETITIVE LANDSCAPE

8.1. Participant Overview

8.2. Company Market Position Analysis

8.3. Company Categorization

8.4. Strategy Mapping

8.5. Company Profiles/Listing

8.5.1. Novo Nordisk A/S

- 8.5.1.1. Overview
- 8.5.1.2. Financial Performance
- 8.5.1.3. Type Benchmarking
- 8.5.1.4. Strategic Initiatives

8.5.2. Pfizer Inc.

- 8.5.2.1. Overview
- 8.5.2.2. Financial Performance
- 8.5.2.3. Type Benchmarking
- 8.5.2.4. Strategic Initiatives

8.5.3. Eli Lilly and Company

- 8.5.3.1. Overview
- 8.5.3.2. Financial Performance
- 8.5.3.3. Type Benchmarking
- 8.5.3.4. Strategic Initiatives

8.5.4. Medical Device Business Services, Inc.

- 8.5.4.1. Overview
- 8.5.4.2. Financial Performance
- 8.5.4.3. Type Benchmarking
- 8.5.4.4. Strategic Initiatives

8.5.5. Johnson & Johnson Services, Inc.

- 8.5.5.1. Overview
- 8.5.5.2. Financial Performance
- 8.5.5.3. Type Benchmarking
- 8.5.5.4. Strategic Initiatives

8.5.6. Stryker

- 8.5.6.1. Overview
- 8.5.6.2. Financial Performance
- 8.5.6.3. Type Benchmarking
- 8.5.6.4. Strategic Initiatives

8.5.7. Ultragenyx Pharmaceutical Inc.

- 8.5.7.1. Overview
- 8.5.7.2. Financial Performance
- 8.5.7.3. Type Benchmarking
- 8.5.7.4. Strategic Initiatives

8.5.8. Alexion Pharmaceuticals, Inc.

- 8.5.8.1. Overview
- 8.5.8.2. Financial Performance
- 8.5.8.3. Type Benchmarking

8.5.8.4. Strategic Initiatives

List Of Tables

LIST OF TABLES

Table 1. List of secondary sources

Table 2. List of abbreviations

Table 3. Global somatostatin analogs market, by region, 2018 - 2030 (USD Million)

Table 4. Global somatostatin analogs market, by type, 2018 - 2030 (USD Million)

Table 5. Global somatostatin analogs market, by application, 2018 - 2030 (USD Million)

Table 6. Global somatostatin analogs market, by end use, 2018 - 2030 (USD Million)

Table 7. North America somatostatin analogs market, by country, 2018 - 2030 (USD Million)

Table 8. North America somatostatin analogs market, by type, 2018 - 2030 (USD Million)

Table 9. North America somatostatin analogs market, by application, 2018 - 2030 (USD Million)

Table 10. North America somatostatin analogs market, by end use, 2018 - 2030 (USD Million)

Table 11. U.S. somatostatin analogs market, by type, 2018 - 2030 (USD Million)

Table 12. U.S. somatostatin analogs market, by application, 2018 - 2030 (USD Million)

Table 13. U.S. somatostatin analogs market, by end use, 2018 - 2030 (USD Million)

Table 14. Canada somatostatin analogs market, by type, 2018 - 2030 (USD Million)

Table 15. Canada somatostatin analogs market, by application, 2018 - 2030 (USD Million)

Table 16. Canada somatostatin analogs market, by end use, 2018 - 2030 (USD Million)

Table 17. Mexico somatostatin analogs market, by type, 2018 - 2030 (USD Million)

Table 18. Mexico somatostatin analogs market, by application, 2018 - 2030 (USD Million)

Table 19. Mexico somatostatin analogs market, by end use, 2018 - 2030 (USD Million)

Table 20. Europe somatostatin analogs market, by country, 2018 - 2030 (USD Million)

Table 21. Europe somatostatin analogs market, by type, 2018 - 2030 (USD Million)

Table 22. Europe somatostatin analogs market, by application, 2018 - 2030 (USD Million)

Table 23. Europe somatostatin analogs market, by end use, 2018 - 2030 (USD Million)

Table 24. UK somatostatin analogs market, by type, 2018 - 2030 (USD Million)

Table 25. UK somatostatin analogs market, by application, 2018 - 2030 (USD Million)

Table 26. UK somatostatin analogs market, by end use, 2018 - 2030 (USD Million)

Table 27. Germany somatostatin analogs market, by type, 2018 - 2030 (USD Million)

Table 28. Germany somatostatin analogs market, by application, 2018 - 2030 (USD Million)

Million)

Table 29. Germany somatostatin analogs market, by end use, 2018 - 2030 (USD Million)

Table 30. France somatostatin analogs market, by type, 2018 - 2030 (USD Million)

Table 31. France somatostatin analogs market, by application, 2018 - 2030 (USD Million)

Table 32. France somatostatin analogs market, by end use, 2018 - 2030 (USD Million)

Table 33. Italy somatostatin analogs market, by type, 2018 - 2030 (USD Million)

Table 34. Italy somatostatin analogs market, by application, 2018 - 2030 (USD Million)

Table 35. Italy somatostatin analogs market, by end use, 2018 - 2030 (USD Million)

Table 36. Spain somatostatin analogs market, by type, 2018 - 2030 (USD Million)

Table 37. Spain somatostatin analogs market, by application, 2018 - 2030 (USD Million)

Table 38. Spain somatostatin analogs market, by end use, 2018 - 2030 (USD Million)

Table 39. Denmark somatostatin analogs market, by type, 2018 - 2030 (USD Million)

Table 40. Denmark somatostatin analogs market, by application, 2018 - 2030 (USD Million)

Table 41. Denmark somatostatin analogs market, by end use, 2018 - 2030 (USD Million)

Table 42. Sweden somatostatin analogs market, by type, 2018 - 2030 (USD Million)

Table 43. Sweden somatostatin analogs market, by application, 2018 - 2030 (USD Million)

Table 44. Sweden somatostatin analogs market, by end use, 2018 - 2030 (USD Million)

Table 45. Norway somatostatin analogs market, by type, 2018 - 2030 (USD Million)

Table 46. Norway somatostatin analogs market, by application, 2018 - 2030 (USD Million)

Table 47. Norway somatostatin analogs market, by end use, 2018 - 2030 (USD Million)

Table 48. Russia somatostatin analogs market, by type, 2018 - 2030 (USD Million)

Table 49. Russia somatostatin analogs market, by application, 2018 - 2030 (USD Million)

Table 50. Russia somatostatin analogs market, by end use, 2018 - 2030 (USD Million)

Table 51. Asia Pacific somatostatin analogs market, by country, 2018 - 2030 (USD Million)

Table 52. Asia Pacific somatostatin analogs market, by type, 2018 - 2030 (USD Million)

Table 53. Asia Pacific somatostatin analogs market, by application, 2018 - 2030 (USD Million)

Table 54. Asia Pacific somatostatin analogs market, by end use, 2018 - 2030 (USD Million)

Table 55. India somatostatin analogs market, by type, 2018 - 2030 (USD Million)

Table 56. India somatostatin analogs market, by application, 2018 - 2030 (USD Million)

Table 57. India somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
Table 58. China somatostatin analogs market, by type, 2018 - 2030 (USD Million)
Table 59. China somatostatin analogs market, by application, 2018 - 2030 (USD Million)
Table 60. China somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
Table 61. South Korea somatostatin analogs market, by type, 2018 - 2030 (USD Million)
Table 62. South Korea somatostatin analogs market, by application, 2018 - 2030 (USD Million)
Table 63. South Korea somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
Table 64. Hong Kong somatostatin analogs market, by type, 2018 - 2030 (USD Million)
Table 65. Hong Kong somatostatin analogs market, by application, 2018 - 2030 (USD Million)
Table 66. Hong Kong somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
Table 67. Australia somatostatin analogs market, by type, 2018 - 2030 (USD Million)
Table 68. Australia somatostatin analogs market, by application, 2018 - 2030 (USD Million)
Table 69. Australia somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
Table 70. Singapore somatostatin analogs market, by type, 2018 - 2030 (USD Million)
Table 71. Singapore somatostatin analogs market, by application, 2018 - 2030 (USD Million)
Table 72. Singapore somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
Table 73. Japan somatostatin analogs market, by type, 2018 - 2030 (USD Million)
Table 74. Japan somatostatin analogs market, by application, 2018 - 2030 (USD Million)
Table 75. Japan somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
Table 76. Thailand somatostatin analogs market, by type, 2018 - 2030 (USD Million)
Table 77. Thailand somatostatin analogs market, by application, 2018 - 2030 (USD Million)
Table 78. Thailand somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
Table 79. Latin America somatostatin analogs market, by country, 2018 - 2030 (USD Million)
Table 80. Latin America somatostatin analogs market, by type, 2018 - 2030 (USD Million)
Table 81. Latin America somatostatin analogs market, by application, 2018 - 2030 (USD Million)
Table 82. Latin America somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
Table 83. Brazil somatostatin analogs market, by type, 2018 - 2030 (USD Million)

Table 84. Brazil somatostatin analogs market, by application, 2018 - 2030 (USD Million)

Table 85. Brazil somatostatin analogs market, by end use, 2018 - 2030 (USD Million)

Table 86. Argentina somatostatin analogs market, by type, 2018 - 2030 (USD Million)

Table 87. Argentina somatostatin analogs market, by application, 2018 - 2030 (USD Million)

Table 88. Argentina somatostatin analogs market, by end use, 2018 - 2030 (USD Million)

Table 89. Middle East & Africa somatostatin analogs market, by country, 2018 - 2030 (USD Million)

Table 90. Middle East & Africa somatostatin analogs market, by type, 2018 - 2030 (USD Million)

Table 91. Middle East & Africa somatostatin analogs market, by application, 2018 - 2030 (USD Million)

Table 92. Middle East & Africa somatostatin analogs market, by end use, 2018 - 2030 (USD Million)

Table 93. Kuwait somatostatin analogs market, by type, 2018 - 2030 (USD Million)

Table 94. Kuwait somatostatin analogs market, by application, 2018 - 2030 (USD Million)

Table 95. Kuwait somatostatin analogs market, by end use, 2018 - 2030 (USD Million)

Table 96. Saudi Arabia somatostatin analogs market, by type, 2018 - 2030 (USD Million)

Table 97. Saudi Arabia somatostatin analogs market, by application, 2018 - 2030 (USD Million)

Table 98. Saudi Arabia somatostatin analogs market, by end use, 2018 - 2030 (USD Million)

Table 99. South Africa somatostatin analogs market, by type, 2018 - 2030 (USD Million)

Table 100. South Africa somatostatin analogs market, by application, 2018 - 2030 (USD Million)

Table 101. South Africa somatostatin analogs market, by end use, 2018 - 2030 (USD Million)

Table 102. UAE somatostatin analogs market, by type, 2018 - 2030 (USD Million)

Table 103. UAE somatostatin analogs market, by application, 2018 - 2030 (USD Million)

Table 104. UAE somatostatin analogs market, by end use, 2018 - 2030 (USD Million)

List Of Figures

LIST OF FIGURES

- Fig. 1 Somatostatin analogs market segmentation
- Fig. 2 Market research process
- Fig. 3 Data triangulation techniques
- Fig. 4 Primary research pattern
- Fig. 5 Market research approaches
- Fig. 6 Value-chain-based sizing & forecasting
- Fig. 7 Market formulation & validation
- Fig. 8 Market snapshot
- Fig. 9 Type outlook (USD Million)
- Fig. 10 Application outlook (USD Million)
- Fig. 11 End Use outlook (USD Million)
- Fig. 12 Competitive landscape
- Fig. 13 Somatostatin analogs market dynamics
- Fig. 14 Somatostatin analogs market: Porter's five forces analysis
- Fig. 15 Somatostatin analogs market: Pestle analysis
- Fig. 16 Somatostatin analogs market: Type segment dashboard
- Fig. 17 Somatostatin analogs market: Type market share analysis, 2024 & 2030
- Fig. 18 Octreotide market, 2018 - 2030 (USD Million)
- Fig. 19 Lanreotide market, 2018 - 2030 (USD Million)
- Fig. 20 Pasireotide market, 2018 - 2030 (USD Million)
- Fig. 21 Others market, 2018 - 2030 (USD Million)
- Fig. 22 Somatostatin analogs market: Application segment dashboard
- Fig. 23 Somatostatin analogs market: Application market share analysis, 2024 & 2030
- Fig. 24 Somatostatin analogs market, in Acromegaly, 2018 - 2030 (USD Million)
- Fig. 25 Somatostatin analogs market, in NET, 2018 - 2030 (USD Million)
- Fig. 26 Somatostatin analogs market, in Others, 2018 - 2030 (USD Million)
- Fig. 27 Somatostatin analogs market: End Use segment dashboard
- Fig. 28 Somatostatin analogs market: End Use market share analysis, 2024 & 2030
- Fig. 29 Hospitals segment market, 2018 - 2030 (USD Million)
- Fig. 30 Clinics segment market, 2018 - 2030 (USD Million)
- Fig. 31 Others segment market, 2018 - 2030 (USD Million)
- Fig. 32 Somatostatin analogs market revenue, by region
- Fig. 33 Regional marketplace: Key takeaways
- Fig. 34 Regional marketplace: Key takeaways
- Fig. 35 North America somatostatin analogs market, 2018 - 2030 (USD Million)

- Fig. 36 U.S. country dynamics
- Fig. 37 U.S. somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 38 Canada country dynamics
- Fig. 39 Canada somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 40 Mexico country dynamics
- Fig. 41 Mexico somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 42 Europe somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 43 UK country dynamics
- Fig. 44 UK somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 45 Germany country dynamics
- Fig. 46 Germany somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 47 France country dynamics
- Fig. 48 France somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 49 Italy country dynamics
- Fig. 50 Italy somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 51 Spain country dynamics
- Fig. 52 Spain somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 53 Denmark country dynamics
- Fig. 54 Denmark somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 55 Sweden country dynamics
- Fig. 56 Sweden somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 57 Norway country dynamics
- Fig. 58 Norway somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 59 Russia country dynamics
- Fig. 60 Russia somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 61 Asia Pacific somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 62 India country dynamics
- Fig. 63 India somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 64 China country dynamics
- Fig. 65 China somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 66 South Korea country dynamics
- Fig. 67 South Korea somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 68 Hong Kong country dynamics
- Fig. 69 Hong Kong somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 70 Australia country dynamics
- Fig. 71 Australia somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 72 Singapore country dynamics
- Fig. 73 Singapore somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 74 Japan country dynamics

- Fig. 75 Japan somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 76 Thailand country dynamics
- Fig. 77 Thailand somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 78 Latin America somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 79 Brazil country dynamics
- Fig. 80 Brazil somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 81 Argentina country dynamics
- Fig. 82 Argentina somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 83 Middle East & Africa somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 84 South Africa country dynamics
- Fig. 85 South Africa somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 86 Kuwait country dynamics
- Fig. 87 Kuwait somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 88 Saudi Arabia country dynamics
- Fig. 89 Saudi Arabia somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 90 South Africa country dynamics
- Fig. 91 South Africa somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 92 UAE country dynamics
- Fig. 93 UAE somatostatin analogs market, 2018 - 2030 (USD Million)
- Fig. 94 Company categorization
- Fig. 95 Company market position analysis
- Fig. 96 Strategic framework

I would like to order

Product name: Somatostatin Analogs Market Size, Share & Trends Analysis Report By Type (Octreotide, Lanreotide, Pasireotide), By Application (Acromegaly, NET), By End-use (Hospitals, Clinics), By Region, And Segment Forecasts, 2025 - 2030

Product link: <https://marketpublishers.com/r/SDB2F6B49E4EEN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SDB2F6B49E4EEN.html>